Program
GS1-144
Also written as “GS1-144 tablet”, “GS1-144 tablets” and “[14C]GS1-144”.
Its studies are led by Changchun GeneScience Pharmaceutical.
Furthest: phase 2, since Dec 5, 20246 company-led studies, 2 open or runningNext primary completion: Jan 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 62 open or running | phase 2since Dec 5, 2024 | Jan 3, 2024 | Jan 31, 2027phase 1 · NCT07491289 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 3, 2024First study: phase 1 study in Vasomotor SymptomsFirst studyNCT06204250 · 86 enrolled · Australia
- Apr 11, 2024Phase 1 study in Vasomotor System; LabileNCT06385158 · 110 enrolled · China
- Dec 5, 2024Phase 2 study in Vasomotor SyndromeNCT06726850 · 129 enrolled · China
- Mar 18, 20262 phase 1 studiesNCT07491289, NCT07534176
- Apr 7, 2026Phase 1 study in Healthy Postmenopausal WomenNCT07537231 · 6 enrolled · China
Ahead
- Jan 31, 2027Primary completion: phase 1 study in Hepatic Impairment and Healthy FemaleNCT07491289
TargetBeta
TACR3 →read by rule
“GS1-144 tablet is an NK3R antagonist.”study text, by rule · the study
Other programs on TACR3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elinzanetantrule | Bayer | phase 3 | 24 |
| fezolinetantrule | Astellas Pharma | phase 3 | 21 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07537231Healthy Postmenopausal Women · China | 1 | Active, not recruiting | Apr 18, 2026 | 6 |
| NCT07534176Postmenopause · China | 1 | Completed | Jul 2, 2026 | 24 |
| NCT07491289Hepatic Impairment and Healthy Female · China | 1 | Not yet recruiting | Jan 31, 2027 | 24 |
| NCT06726850Vasomotor Syndrome · China | 2 | Completed | Apr 17, 2025 | 129 |
| NCT06385158Vasomotor System; Labile · China | 1 | Completed | Jan 6, 2024 | 110 |
| NCT06204250Vasomotor Symptoms · Australia | 1 | Completed | Dec 19, 2024 | 86 |
How it is read
Names in the registry
- “GS1-144”, 2 entries
- “GS1-144 tablet”, 2 entries
- “GS1-144 tablets”, 1 entry
- “[14C]GS1-144”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.